Next, we investigated the correlations between SETD2 mutation and various immune signatures, including 28 tumor-infiltrating lymphocytes, 24 immunoinhibitors, 45 immunostimulators, 21 major histocompatibility complex molecules, 40 chemokines, and 18 chemokine receptors, in kidney renal clear cell carcinoma (KIRC, n = 43), colon adenocarcinoma (COAD, n = 41), lung adenocarcinoma (LUAD, n = 30), bladder urothelial carcinoma (BLCA, n = 27), and uterine corpus endometrial carcinoma (UCEC, n = 22), five tumors with over 20 SETD2 mutant cases in TCGA cohort (Fig. 2). This evidence concerns the gene SETD2 and lung adenocarcinoma.